New hope for Long-Term bipolar depression treatment
NCT ID NCT07217860
Summary
This study aims to understand the long-term safety and effectiveness of the drug azetukalner for adults with bipolar depression. It is open to 400 participants who successfully completed a previous Phase 3 trial of the same drug. The main goal is to monitor side effects and see if the drug continues to help manage depression symptoms over an extended period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel iResearch
Decatur, Georgia, 30030, United States
-
Clinical Neuroscience Solutions
Orlando, Florida, 32801, United States
-
Clinical Neuroscience Solutions Memphis
Memphis, Tennessee, 38119, United States
-
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, 32256, United States
-
Denali Health Atlanta, LLC
Stone Mountain, Georgia, 30083, United States
-
Grayline Research Center
Wichita Falls, Texas, 76309, United States
-
Lumina Clinical Research Center
Cherry Hill, New Jersey, 92866, United States
-
Neurobehavioral Research Inc
Cedarhurst, New York, 11516, United States
-
Woodland International Research Group
Little Rock, Arkansas, 72211, United States
-
Woodland Research Northwest
Rogers, Arkansas, 72758, United States
Conditions
Explore the condition pages connected to this study.